Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

The clinical implications of ADAMTS13 function: the perspectives of haemostaseologists.

Rangarajan S, Kessler C, Aledort L.

Thromb Res. 2013 Oct;132(4):403-7. doi: 10.1016/j.thromres.2013.07.027. Epub 2013 Aug 13. Review.

PMID:
24050828
2.

[ADAMTS13, von Willebrand factor specific cleaving protease].

Veyradier A, Coppo P.

Med Sci (Paris). 2011 Dec;27(12):1097-105. doi: 10.1051/medsci/20112712016. Epub 2011 Dec 23. Review. French.

3.
4.

A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.

Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ.

Blood. 2005 Nov 1;106(9):3035-42. Epub 2005 Jul 12.

5.

ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.

Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR.

Blood. 2007 Mar 1;109(5):1998-2000. Epub 2006 Oct 19.

6.

[Genetic polymorphism of von Willebrand factor (VWF)-cleaving protease, ADAMTS13].

Kokame K.

Brain Nerve. 2008 Nov;60(11):1325-32. Review. Japanese.

PMID:
19069166
7.

Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood.

Donadelli R, Orje JN, Capoferri C, Remuzzi G, Ruggeri ZM.

Blood. 2006 Mar 1;107(5):1943-50. Epub 2005 Nov 17.

8.

Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons.

Feys HB, Roodt J, Vandeputte N, Pareyn I, Mottl H, Hou S, Lamprecht S, Van Rensburg WJ, Deckmyn H, Vanhoorelbeke K.

Blood. 2012 Oct 25;120(17):3611-4. doi: 10.1182/blood-2012-04-421248. Epub 2012 Jul 31.

9.

Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis.

McGrath RT, van den Biggelaar M, Byrne B, O'Sullivan JM, Rawley O, O'Kennedy R, Voorberg J, Preston RJ, O'Donnell JS.

Blood. 2013 Dec 12;122(25):4107-10. doi: 10.1182/blood-2013-04-496851. Epub 2013 Oct 8.

10.

C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor.

Casonato A, Pontara E, Battiston M, Morpurgo M, Cattini MG, Casarin E, Saga G, Daidone V, De Marco L.

Thromb Haemost. 2013 Jun;109(6):999-1006. doi: 10.1160/TH12-11-0808. Epub 2013 Feb 28.

PMID:
23446343
11.

Regulation of von Willebrand factor-platelet interactions.

Lenting PJ, Pegon JN, Groot E, de Groot PG.

Thromb Haemost. 2010 Sep;104(3):449-55. doi: 10.1160/TH09-11-0777. Epub 2010 Jun 10. Review.

PMID:
20539912
12.

The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure?

Claus RA, Bockmeyer CL, Sossdorf M, Lösche W.

Curr Mol Med. 2010 Mar;10(2):236-48. Review.

PMID:
20196724
13.

Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction.

Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H.

J Thromb Haemost. 2006 Nov;4(11):2490-3. Epub 2006 Aug 8. No abstract available.

14.

Insights into von Willebrand factor proteolysis: clinical implications.

Bowen DJ, Collins PW.

Br J Haematol. 2006 Jun;133(5):457-67. Review.

PMID:
16681634
15.

Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.

Lian EC.

Semin Thromb Hemost. 2005 Dec;31(6):625-32. Review.

PMID:
16388413
16.

The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction.

Austin SK, Starke RD, Lawrie AS, Cohen H, Machin SJ, Mackie IJ.

Br J Haematol. 2008 May;141(4):536-44. doi: 10.1111/j.1365-2141.2008.07074.x. Epub 2008 Mar 12.

PMID:
18341632
17.

Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro.

Wang A, Liu F, Dong N, Ma Z, Zhang J, Su J, Zhao Y, Ruan C.

Thromb Res. 2010 Oct;126(4):e260-5. doi: 10.1016/j.thromres.2010.07.009. Epub 2010 Aug 11.

PMID:
20705333
18.

Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy.

Chung MC, Popova TG, Jorgensen SC, Dong L, Chandhoke V, Bailey CL, Popov SG.

J Biol Chem. 2008 Apr 11;283(15):9531-42. doi: 10.1074/jbc.M705871200. Epub 2008 Feb 8.

19.

Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.

Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG, Dong JF, Moake JL.

Blood. 2005 Dec 15;106(13):4199-209. Epub 2005 Aug 30.

20.

Modeling ADAMTS13-von Willebrand factor interaction: Implications for oxidative stress-related cardiovascular diseases and type 2A von Willebrand disease.

Pozzi N, Lancellotti S, De Cristofaro R, De Filippis V.

Biophys Chem. 2012 Jan;160(1):1-11. doi: 10.1016/j.bpc.2011.07.007. Epub 2011 Aug 3.

PMID:
21937160
Items per page

Supplemental Content

Write to the Help Desk